Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login



Effectiveness of the seasonal flu vaccine and new production methods

Despite a mismatch between the 2014–2015 seasonal flu vaccine and circulating strains, the flu jab is still the best way to protect people in at-risk groups.

Viral challenge

There are three types of influenza viruses – A, B and C – but only types A and B cause seasonal epidemics in humans. Type A viruses can also cause pandemics and are classified into subtypes according to the variety and combinations of two surface proteins, hemagglutinin (HA) and neuraminidase (NA). Circulating flu viruses continuously evolve, so seasonal vaccines contain a mix of two influenza A subtypes and one or two influenza B viruses, which are reviewed each year by the World Health Organization (WHO).

Impact and challenges of the flu virus


Vaccine effectiveness

The WHO coordinates a network called the Global Influenza Surveillance and Response System (GISRS), consisting of 142 National Influenza Centres (NICs) as well as various collaborating centres and laboratories. Recommendations for vaccine composition are made by the WHO in February for the following winter’s flu season in the Northern hemisphere. Antigenic drift of circulating viruses can occur in the interim, leading to a mismatch between the vaccine and circulating strains, and low vaccine effectiveness.

Effectiveness of the different flu vaccines


Speeding up production

Traditional egg-based vaccine production is more than 70 years old, takes around six months and uses millions of chicken eggs. Alternative production processes have been developed that aim to speed up manufacturing time and scale-up, as well as improve vaccine efficacy. Importantly, these processes do not rely on eggs, which could be in scarce supply if a bird flu pandemic hits.

Speeding up production go the flu vaccine


Working towards a universal vaccine

Many researchers are trying to create a vaccine that provides broad protection against existing and newly emergent strains, eliminating the need for annual vaccination. Some universal flu vaccines aim to stimulate a cellular immune response, as opposed to the antibody-based response targeted by current vaccines. A cellular response is the mechanism underlying naturally acquired immunity. Even a vaccine more broadly protective within a single subgroup would offer advantages, and could provide some intra-seasonal protection, most likely in combination with conventional vaccines.

Working towards a universal flu vaccine


Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069647

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Impact and challenges of the flu virus
  • Effectiveness of the different flu vaccines
  • Speeding up production go the flu vaccine
  • Working towards a universal flu vaccine

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.